Incyte Corporation

INCY • Biotechnology

$126.75

▼ -1.25 (-0.98%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$26.39B

Crecimiento

27.3%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 25.0%Crecimiento positivo de ingresos · 18.1%Flujo de caja libre positivo · 6.94Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 14.98

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$126.75

Change-0.98%

Shares Out208.22M

Market Cap$26.39B

Enterprise Value$21.89B

52W Range73.81 - 132.60

Beta0.76

P/E16.37

P/S4.53

P/B4.16

P/FCF13.74

EV/Sales3.76

Price$126.75

Change-0.98%

Shares Out208.22M

Market Cap$26.39B

Enterprise Value$21.89B

52W Range73.81 - 132.60

Beta0.76

P/E16.37

P/S4.53

P/B4.16

P/FCF13.74

EV/Sales3.76

EV/EBITDA10.72

EV/FCF11.40

Earnings Yield6.11%

FCF Yield7.28%

Dividend Yield0.00%

Gross Margin92.76%

Oper. Margin26.12%

Profit Margin25.03%

Debt/Eq0.01

Current Ratio3.32

Quick Ratio3.25

Revenue 5Y27.27%

Target$130.07

Target Upside2.62%

Target Median$130.00

Target Range104.00 - 155.00

Volume2.83M

Avg Volume1.82M

EPS Surprise0.43

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

78/100

Por qué este puntaje▼

Márgenes estables o en mejora · 25.0%Crecimiento positivo de ingresos · 18.1%Flujo de caja libre positivo · 6.94Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 14.98Nivel de deuda manejable · 0.01

Analyst view

Analyst sentiment and price target

INCY

Analyst sentiment

Based on 44 analyst votes · 2026-09-05

75/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-30

Bajo

$99.00

Promedio

$124.08

Mediana

$119.50

Alto

$150.00

Resumen de la compañía

IPO: 11/4/1993

Industria: Biotechnology

P/B i: 4.16

Deuda / Patrimonio i: 0.01

Margen operativo: 26.12%

Margen neto: 25.03%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 3.32

Ratio rápido: 3.25

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Heeson Lee

Transacción: 07/23/2026

COMPRA

Cambio

+13,498

Precio

Not reported

Presentación

07/27/2026

Tipo

COMPRA

Heeson Lee

Transacción: 07/23/2026

COMPRA

Cambio

+15,423

Precio

$116.69

Presentación

07/27/2026

Tipo

COMPRA

Morrissey Michael James

Transacción: 07/23/2026

COMPRA

Cambio

+6,426

Precio

$116.69

Presentación

07/27/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Heeson Lee	COMPRA	+13,498	Not reported	07/23/2026	07/27/2026
Heeson Lee	COMPRA	+15,423	$116.69	07/23/2026	07/27/2026
Morrissey Michael James	COMPRA	+6,426	$116.69	07/23/2026	07/27/2026
Morrissey Michael James	COMPRA	+8,999	Not reported	07/23/2026	07/27/2026
Meury William	COMPRA	+77,148	$116.65	07/16/2026	07/20/2026
Meury William	COMPRA	+80,421	Not reported	07/16/2026	07/20/2026
Meury William	COMPRA	+26,807	Not reported	07/16/2026	07/20/2026
Hoffman Richard A.	COMPRA	+7,395	Not reported	07/16/2026	07/20/2026
Hoffman Richard A.	COMPRA	+18,487	Not reported	07/16/2026	07/20/2026
Hoffman Richard A.	COMPRA	+31,923	$116.65	07/16/2026	07/20/2026
Gardner David H	COMPRA	+7,395	Not reported	07/16/2026	07/20/2026
Gardner David H	COMPRA	+18,487	Not reported	07/16/2026	07/20/2026
Gardner David H	COMPRA	+31,923	$116.65	07/16/2026	07/20/2026
Basi Ramitpal K	COMPRA	+4,991	Not reported	07/16/2026	07/20/2026
Basi Ramitpal K	COMPRA	+12,479	Not reported	07/16/2026	07/20/2026
Basi Ramitpal K	COMPRA	+21,548	$116.65	07/16/2026	07/20/2026
Issa Mohamed Khairie	COMPRA	+19,643	Not reported	07/16/2026	07/20/2026
Issa Mohamed Khairie	COMPRA	+33,918	$116.65	07/16/2026	07/20/2026
Issa Mohamed Khairie	VENTA	-1,093	$115.01	07/16/2026	07/20/2026
CAGNONI PABLO J	COMPRA	+33,508	Not reported	07/16/2026	07/20/2026

Sobre la compañía

Incyte Corporation

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Fuente - Link

Competidores

BIIB DGX GMAB ILMN RPRX THC UTHR WAT WST ZBH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.

Seeking Alpha

84,502 Shares in Incyte Corporation $INCY Bought by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 84,502 shares of the biopharmaceutical company's stock, valued at approximately $9,579,000. Several other large investors have also recently bought and

Defense World

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.

GlobeNewsWire

Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More

Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck and Co., Shopify, TJX Companies, and More

247 Wallst

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-28	1.38	1.81	0.43
2026-02-10	1.9	1.8	-0.1
2025-10-28	1.66	2.26	0.6
2025-07-29	1.39	1.57	0.18
2025-04-29	1.01	1.16	0.15
2025-02-10	1.57	1.43	-0.14
2024-10-29	1.12	1.07	-0.05
2024-07-30	0.78	-1.82	-2.6
2024-04-30	0.84	0.64	-0.2
2024-02-13	1.16	1.06	-0.1
2023-10-31	1.09	1.1	0.01
2023-08-01	0.83	0.99	0.16